Skip to main content
. 2016 Sep 30;5(11):e1238541. doi: 10.1080/2162402X.2016.1238541

Figure 2.

Figure 2.

CCL22-reactive T cells are able to recognize and kill CCL22-expressing cancer cell lines. 51Cr release assays of IFNγ non-treated or pretreated cancer cell lines: RPMI6666—Hodgkin's lymphoma (A); Set-2—essential thrombocytemia (B); THP-1—acute monocytic leukemia (C). The same effector CCL22-specific T cell culture was used as effector cells. (D) CCL22 expression in the supernatant of cancer cell lines as measured by CCL22 ELISA. (E) Lysis of IFNγ induced THP-1 cells transfected with CCL22 siRNA transfection or Mock transected by CCL22-specific T cells. Assay performed 48 h after transfection. (F) ELISA analysis of CCL22 expression in the supernatant from siRNA transfected THP-1 cells compared to THP-1 cells transfected with Mock control, 48 h after electroporation.